# US 10,500,238 B2 · Use of gram negative species to treat atopic dermatitis > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 10,500,238 B2 - Document ID: US10500238B2 - Status: Granted - Kind: B2 - Application number: 16/271,552 - Filed: 2019-02-08 - Published: 2019-06-13 - Granted: 2019-12-10 - Earliest claimed: 2016-04-19 - Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services - Applicants: The United States of America, as Represented by the Secretary, Department of Health and Human Serv - Inventors: Ian Antheni Myles; Sandip K. Datta - Web page: https://patentgrep.com/patent/US10500238B2 ## CPC - A61K 35/74: Bacteria (therapeutic use of a bacterial protein A61K38/00) - A61P 17/04: Antipruritics - A61K 9/0014: {Skin, i.e. galenical aspects of topical compositions (non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00)} - A61K 9/06: Ointments; Bases therefor; {Other semi-solid forms, e.g. creams, sticks, gels (composition of ointments, creams or gels A61K47/00)} - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS ## Abstract Pharmaceutical compositions are disclosed that includes a therapeutically effective amount of a purified viable Gram negative bacteria and a pharmaceutically acceptable carrier. The pharmaceutical compositions are formulated for topical administration. Methods of treating atopic dermatitis using these pharmaceutical compositions are also disclosed. ## Claims ### Claim 1 A method for treatment of atopic dermatitis, comprising: topically administering to a subject in need thereof a pharmaceutical composition comprising at least one strain of Roseomonas mucosa, wherein the at least one strain of Roseomonas mucosa comprises a nucleic acid sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, and SEQ ID NO: 3, and wherein the at least one strain of Roseomonas mucosa is present in an amount sufficient for treatment of atopic dermatitis in the subject. ### Claim 2 (depends on 1) The method of claim 1, wherein the pharmaceutical composition further comprises a carrier. ### Claim 3 (depends on 2) The method of claim 2, wherein the carrier comprises sucrose. ### Claim 4 (depends on 1) The method of claim 1, wherein the at least one strain of Roseomonas mucosa is isolated from a subject that does not have atopic dermatitis. ### Claim 5 (depends on 1) The method of claim 1, wherein the pharmaceutical composition is in a topical dosage form selected from the group consisting of a cream, gel, foam, ointment, and lotion. ### Claim 6 (depends on 1) The method of claim 1, wherein the at least one strain of Roseomonas mucosa is topically administered to the subject 1, 2, 3, 4, or 5 times per day. ### Claim 7 (depends on 1) The method of claim 1, wherein the at least one strain of Roseomonas mucosa is topically administered to the subject at least two times per a week. ### Claim 8 (depends on 1) The method of claim 1, wherein the at least one strain of Roseomonas mucosa is topically administered to the subject daily over a week. ### Claim 9 (depends on 1) The method of claim 1, wherein the at least one strain of Roseomonas mucosa is topically administered to the subject 3, 4, 5, or 6 times per week. ### Claim 10 (depends on 1) The method of claim 1, wherein the subject is an adult. ### Claim 11 (depends on 1) The method of claim 1, wherein the subject is a child. ### Claim 12 (depends on 1) The method of claim 1, wherein the subject is an infant. ### Claim 13 (depends on 1) The method of claim 1, wherein the at least one strain of Roseomonas mucosa comprises the nucleic acid sequence of SEQ ID NO: 1. ### Claim 14 (depends on 1) The method of claim 1, wherein the at least one strain of Roseomonas mucosa comprises the nucleic acid sequence of SEQ ID NO: 2. ### Claim 15 (depends on 1) The method of claim 1, wherein the at least one strain of Roseomonas mucosa comprises the nucleic acid sequence of SEQ ID NO: 3. ### Claim 16 (depends on 1) The method of claim 1, wherein the at least one strain of Roseomonas mucosa comprises a mixture of three strains of Roseomonas mucosa, wherein each of said strains comprises one of the nucleic acid sequences selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, and SEQ ID NO: 3. ### Claim 17 (depends on 1) The method of claim 1, wherein the at least one strain of Roseomonas mucosa is present in the pharmaceutical composition in a total amount of 104 to 1012 colony forming units. ### Claim 18 (depends on 1) The method of claim 1, wherein the at least one strain of Roseomonas mucosa is present in the pharmaceutical composition in a total amount of 104 to 108 colony forming units. ### Claim 19 (depends on 1) The method of claim 1, wherein the at least one strain of Roseomonas mucosa is present in the pharmaceutical composition in a total amount of 105 to 107 colony forming units.